Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY

Vivo Capital LLC lowered its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) by 90.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,137,015 shares of the company’s stock after selling 10,233,137 shares during the quarter. Vivo Capital LLC owned approximately 9.00% of Unicycive Therapeutics worth $5,424,000 at the end of the most recent quarter.

Separately, JPMorgan Chase & Co. lifted its position in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares in the last quarter. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on UNCY shares. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price (up previously from $9.00) on shares of Unicycive Therapeutics in a report on Wednesday, October 29th. Benchmark upped their target price on shares of Unicycive Therapeutics to $21.00 and gave the stock a “speculative buy” rating in a research note on Monday, September 15th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 1st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Unicycive Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.33.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $6.58 on Tuesday. Unicycive Therapeutics, Inc. has a 52 week low of $3.71 and a 52 week high of $11.00. The firm’s 50-day simple moving average is $5.15 and its 200 day simple moving average is $5.06. The firm has a market cap of $141.40 million, a price-to-earnings ratio of -1.67 and a beta of 1.84.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.20. Sell-side analysts anticipate that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current year.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.